# 40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)

> **NCT00159783** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 218 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** asenapine
- **DRUG:** Olanzapine

## Key facts

- **NCT ID:** NCT00159783
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2022-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00159783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00159783, "40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00159783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*